Guidelines and global risk: a U.S. perspective
Weill Medical College of Cornell University, New York, New York, U.S.A.
* Correspondence: Professor Antonio Gotto, Office of the Dean, Weill Medical College of Cornell University, 1300 York Avenue, New York, NY 10021, U.S.A.
Abstract
Several studies have shown that coronary heart disease is poorly controlled in the U.S.A. In particular, in a significant proportion of patients, cholesterol levels are not being measured, and individuals who have been prescribed lipid-lowering medication usually fail to achieve recommended targets. The National Cholesterol Education Program has recently published the recommendations of its third Adult Treatment Panel (ATP III). These guidelines differ from earlier guidelines in several ways. They advocate assessment of global risk in order to determine the type and intensity of treatment employed. Global risk calculation is based on a modified version of the Framingham algorithm, with a point-score system. Although low-density lipoprotein cholesterol continues to be highlighted as the primary target of therapy, ATP 111 for the first time officially defines the metabolic syndrome and considers it a secondary target for treatment. ATP III also recommends non-high-density lipoprotein cholesterol as a secondary target for patients with high triglyceride levels, because data indicate that hypertriglyceridaemia is an independent risk factor for coronary heart disease. Under these new guidelines, three times as many people will qualify for treatment as compared with previous guidelines, representing a large increase in health care expenditure and important new challenges for clinicians.
Key Words: Guidelines • lipids • prevention
References
- Executive Summary of The Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486–2497
[Free Full Text] - Qurcshi AI, Suri ME, Guterman LIZ, Hopkins LN. Ineffective secondary prevention in survivors of cardiovascular events in the US population: report from the Third National Health and Nutrition Examination Survey. Arch Intern Med. 2001;161:1621–1628
[Abstract/Free Full Text] - Pearson TA, Laurora I, Chu H, Kafonek S. The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med. 2000;160:459–467
[Abstract/Free Full Text] - Summary of the Second Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA. 1993;269:3015–3023
[Abstract/Free Full Text] - Yarzebski J, Spencer F, Goldberg RJ, Lessard D, Gore JM. Temporal trends (1986–1997) in cholesterol level assessment and management practices in patients with acute myocardial infarc tion: a population-based perspective. Arch Intern Med. 2001;161:1521–1528
[Abstract/Free Full Text] - Wilson PWF, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97:1837–1847
[Abstract/Free Full Text] - Ballantyne CM. Low-density lipoproteins and risk for coronary artery disease. Am J Cardiol. 1998;82:3Q–12Q[Web of Science][Medline]
- LaRosa JCTNT Steering Committee. Effect of lowering LDL-C beyond currently recommended targets: the Treating to New Targets (TNT) study. Poster presentation at the X111th International Symposium on Drugs Affecting Lipid Metabolism. May 30–June 3 1998. Florence, Italy
- MacMahon M, Kirkpatrick C, Cummings CE, Clayton A, Robinson PJ, Tomiak RH, Liu M, Kush D, Tobert J. A pilot study with simvastatin and folic acid/vitamin B12 in preparation for the Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH). Nutr Metab Cardiovasc Dis. 2000;10:195–203[Web of Science][Medline]
- MRC/BHF Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering therapy and of antioxidant vitamin supplementation in a wide range of patients at increased risk of coronary heart disease death: early safety and efficacy experience. Eur Heart J. 1999;20:725–741
[Abstract/Free Full Text]
CiteULike 
Connotea 
Del.icio.us What's this?
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||